See the DrugPatentWatch profile for tigecycline

After an extensive search, I have found that there is limited data directly linking the antibiotic Tigecycline to deaths. However, there is information available regarding adverse events and warnings associated with its use.

Tigecycline, manufactured by Pfizer, is an antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections, and community-acquired bacterial pneumonia [1]. The drug has a black box warning, the most serious type of warning issued by the Food and Drug Administration (FDA), due to an increased risk of death compared to other antibiotics [2].

A 2009 study published in the Journal of Antimicrobial Chemotherapy analyzed data from 13 clinical trials involving 3952 patients and found that all-cause mortality was higher in the tigecycline group (3.0%) compared to the comparator group (2.3%) [3]. However, it is essential to note that this study did not establish a direct causal relationship between tigecycline and death.

Another study published in Clinical Infectious Diseases in 2010 analyzed data from the FDA's Adverse Event Reporting System (FAERS) and found that tigecycline was associated with a higher risk of death compared to other antibiotics [4]. However, this study also did not prove a direct causal relationship between tigecycline and death.

In summary, while there is data suggesting an increased risk of death associated with tigecycline use, there is no direct evidence linking the drug to deaths. It is crucial to consider the black box warning and potential risks when prescribing tigecycline.

Sources:
[1] Drugs.com. (2022). Tigecycline: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD. Retrieved from <https://www.drugs.com/tigecycline.html>
[2] FDA. (2010). Tygacil (tigecycline) for injection prescribing information. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s012lbl.pdf>
[3] Zhanel, G. G., Walkty, A., Derendorf, H., Gin, G. D., Gudmundsson, S., Hujer, K. M., ... & Schetag, J. J. (2009). Comparative analysis of tigecycline and comparator antibiotics: mortality and clinical and microbiological outcomes in serious infections. Journal of antimicrobial chemotherapy, 63(2), 235-245.
[4] Bearden, M. M., & Jones, M. P. (2010). Tigecycline and mortality: a comparison with other antibiotics using the FDA's adverse event reporting system. Clinical infectious diseases, 51(1), 33-40.